Micreos Proceeds to the finals at Ideas from Europe
Above Mark Offerhaus’ presentation can be seen. Taking place at the semi-finals of Ideas from Europe 2017, Tallinn, Estonia: Bacteria are all around us.
We developed the world’s first targeted antibacterial products, set to replace antibiotics. This unlocks a completely new approach in dealing with the bacteria around us and enables preventive daily therapy against only unwanted bacteria for as long as needed.
Micreos develops the world’s first targeted antibacterial products, set to replace antibiotics. With Micreos endolysin technology, for the first time we can kill only the unwanted bacteria – including antibiotic resistant strains – while preserving the beneficial bacteria, essential for our health. In addition, scientists do not expect emergence of resistance against endolysins, based on their working mechanism. This unlocks a completely new approach in dealing with the bacteria around us – also enabling preventive daily therapy against only unwanted bacteria for as long as needed.
These human health products are marketed under the Gladskin and Staphefekt brands
Under the Phageguard brand Micreos has also developed FDA-approved food safety products against Salmonella and Listeria monocytogenes, which is especially dangerous for pregnant women and for the elderly and immuno-compromised.
Micreos’ technology is applied in many areas, including human health, food safety, animal health and agriculture. Micreos Human Health is based in Bilthoven at the RIVM premises (Dutch NIH). Micreos Food Safety is based in Wageningen ‘Food Valley’. Micreos headquarters are based in The Hague, world capital of Peace and Justice.